Abstract
BACKGROUND AND PURPOSE: Large intracranial vessel occlusion due to calcified emboli is a rare cause of major stroke. We assessed the prevalence, imaging appearance, the effectiveness of mechanical thrombectomy, and clinical outcome of patients with large-vessel occlusion due to calcified emboli.
MATERIALS AND METHODS: We performed a retrospective analysis of clinical and procedural data of consecutive patients who underwent mechanical thrombectomy due to calcified emboli in 7 European stroke centers.
RESULTS: We screened 2969 patients, and 40 patients matched the inclusion criteria, accounting for a prevalence of 1.3%. The mean maximal density of the thrombus was 327 HU (range, 150–1200 HU), and the mean thrombus length was 9.2 mm (range, 4–20 mm). Four patients had multiple calcified emboli, and 2 patients had an embolic event during an endovascular intervention. A modified TICI score of ≥2b was achieved in 57.5% (23/40), with minimal-to-no reperfusion (modified TICI 0–1) in 32.5% (13/40) and incomplete reperfusion (modified TICI 2a) in 10% (4/40). Excellent outcome (mRS 0–1) was achieved in only 20.6%, functional independence (mRS 0–2) in 26.5% and 90-day mortality was 55.9%.
CONCLUSIONS: Acute ischemic stroke with large-vessel occlusion due to calcified emboli is a rare entity in patients undergoing thrombectomy, with considerably worse angiographic outcome and a higher mortality compared with patients with noncalcified thrombi. Good functional recovery at 3 months can still be achieved in about a quarter of patients.
ABBREVIATIONS:
- CLASS
- calcium load assessment
- MT
- mechanical thrombectomy
- mTICI
- modified TICI
Footnotes
Disclosures: Christoph J. Maurer—UNRELATED: Grants/Grants Pending: MicroVention, Stryker, Comments: educational grants. Ansgar Berlis—UNRELATED: Consultancy: proctoring MicroVention, Stryker, Medtronic; Payment for Lectures Including Service on Speakers Bureaus: Penumbra; Other: Clinical Ethics Committee phenox, Comments: Money paid to the individual. Jan Gralla—RELATED: Grant: Medtronic, Comments: Global Principal Investigator of the Swift Direct Study*; Fees for Participation in Review Activities Such as Data Monitoring Boards, Statistical Analysis, Endpoint Committees, and the Like: Penumbra, Comments: CEC of the Promise Study*; UNRELATED: Grants/Grants Pending: Schweizerischer Nationalfonds, Comments: MRI in stroke.* Markus A. Möhlenbruch—UNRELATED: Consultancy: Medtronic, MicroVention, Stryker; Grants/Grants Pending: Balt, MicroVention*; Payment for Lectures Including Service on Speakers Bureaus: Medtronic, MicroVention, Stryker. Kristine A. Blackham—UNRELATED: Consultancy: Medtronic.* Philipp Zickler—UNRELATED: Consultancy: Boehringer-Ingelheim; Payment for Lectures Including Service on Speakers Bureaus: Bristol-Myers-Squibb; Travel/Accommodations/Meeting Expenses Unrelated to Activities Listed: Bayer AG, Daiichi Sankyo. Sebastian Fischer—UNRELATED: Consultancy: MicroVention, phenox, Kaneka, Stryker.* *Money paid to the institution.
- © 2020 by American Journal of Neuroradiology